Brand Names:
Tildren, Equidronate, Tiludronate


Drug Type: Bisphosphonate

Tiludronic acid


Tiludronic acid (Tiludronate) is a biphosphonate used for treatment of navicular disease and bone spavin in horses and Paget's disease of bone (osteitis deformans) in humans.

Tiludronate affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Based on the known action of tiludronate, hypocalcemia is a potential consequence of overdose.
IV injection or orally
  • Overdose: hypocalcemia
  • Acetylsalicylic acid: The serum concentration of Tiludronic acid can be decreased when it is combined with Acetylsalicylic acid.
  • Amikacin: Amikacin may increase the hypocalcemic activities of Tiludronic acid.
  • Apramycin: Apramycin may increase the hypocalcemic activities of Tiludronic acid.
  • Calcium lactate : The serum concentration of Tiludronic acid can be decreased when it is combined with Calcium lactate.
  • Calcium gluconate : The serum concentration of Tiludronic acid can be decreased when it is combined with Calcium gluconate.
  • Carprofen: The risk or severity of adverse effects can be increased when Carprofen is combined with Tiludronic acid.
  • Chloroquine: The risk or severity of adverse effects can be increased when Chloroquine is combined with Tiludronic acid.
  • Diclofenac: The risk or severity of adverse effects can be increased when Diclofenac is combined with Tiludronic acid.
  • The risk or severity of adverse effects can be increased when Diclofenac is combined with Tiludronic acid.: Dihydrostreptomycin may increase the hypocalcemic activities of Tiludronic acid.
  • Evening primrose oil: The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Tiludronic acid.
  • Etodolac: The risk or severity of adverse effects can be increased when Etodolac is combined with Tiludronic acid.
  • Flunixin: The risk or severity of adverse effects can be increased when Flunixin is combined with Tiludronic acid.
  • Gentamicin: Gentamicin may increase the hypocalcemic activities of Tiludronic acid.
  • Hygromycin B: Hygromycin B may increase the hypocalcemic activities of Tiludronic acid.
  • Ketoprofen: The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tiludronic acid.
  • Meloxicam: The risk or severity of adverse effects can be increased when Meloxicam is combined with Tiludronic acid.
  • Magnesium sulfate: The serum concentration of Tiludronic acid can be decreased when it is combined with Magnesium sulfate